Haloperidol Successfully Treated 4 Cases of Cannabinoid Hyperemesis Syndrome That Failed Standard ER Treatments | Research

The takeaway

Four CHS patients who did not respond to standard emergency department antiemetics improved significantly after receiving haloperidol, suggesting dopamine-cannabinoid receptor interactions may explain the treatment's effectiveness.

CHS patients and emergency physicians seeking effective treatment options.

All 4 CHS patients improved with haloperidol after standard antiemetics failed

What the researchers found

Four patients with CHS who failed standard emergency department therapy (including conventional antiemetics) showed significant improvement after treatment with haloperidol, an antipsychotic that primarily blocks dopamine D2 receptors.

The authors propose a mechanistic explanation: CHS involves dysregulation of cannabinoid type 1 (CB1) receptors, and recent animal research has revealed complex interactions between dopamine and CB1 signaling. Haloperidol's success may relate to its ability to modulate these dopamine-cannabinoid interactions rather than through its traditional antiemetic mechanism.

The case series highlights a practical clinical point: CHS patients often undergo excessive laboratory and radiographic testing and require hospital admission because standard antiemetics fail. If haloperidol can quickly resolve symptoms in the emergency department, it could reduce unnecessary testing and admission.

Why it matters

CHS remains a diagnostic and therapeutic challenge in emergency departments. Standard antiemetics frequently fail, leading to prolonged ER stays, excessive workups, and hospital admissions. Haloperidol represents a potentially effective, widely available, and inexpensive treatment option.

The numbers in context

4 patients. All failed standard ED antiemetics. All improved significantly with haloperidol. Complex dopamine-CB1 receptor interactions proposed as mechanism.

How the study worked

Case series of 4 CHS patients treated with haloperidol in the emergency department after failure of standard antiemetic therapy.

What this study cannot tell us

Only 4 cases without controls. Improvement could coincide with natural symptom resolution. Haloperidol has its own side effects (sedation, movement disorders, QT prolongation) that were not discussed. The proposed mechanism is speculative. The optimal haloperidol dose for CHS has not been established.

How to read the evidence

Preliminary evidence from a small case series.

When this study was published

Published in 2017. Haloperidol for CHS has received increasing clinical attention since.

The bigger picture

This case series adds to growing evidence (alongside the systematic review RTHC-01502) that CHS responds better to dopamine-active drugs (haloperidol, droperidol) and benzodiazepines than to traditional antiemetics. The dopamine-cannabinoid receptor interaction hypothesis provides a theoretical framework that could guide future treatment research.

Questions still open

What is the optimal haloperidol dose for CHS? Would other dopamine antagonists (droperidol, olanzapine) work as well? Could haloperidol become a first-line CHS treatment in emergency departments?

Common questions

What is haloperidol and why does it work for CHS?

Haloperidol is an antipsychotic drug that blocks dopamine D2 receptors. It appears to work for CHS because of complex interactions between the dopamine and cannabinoid receptor systems. Unlike standard antiemetics (which target serotonin or histamine receptors), haloperidol addresses a different part of the vomiting circuitry that is disrupted in CHS.

Should I ask for haloperidol if I go to the ER with CHS?

This case series suggests haloperidol may be effective when standard antiemetics fail for CHS. However, it is a prescription medication with side effects and should be prescribed by a physician. Discussing haloperidol as an option with your ER doctor is reasonable if standard treatments are not working.

Read the original research

Haloperidol, a Novel Treatment for Cannabinoid Hyperemesis Syndrome.

American journal of therapeutics, 24(1), e64-e67

View on PubMed ↗Publisher’s paper ↗

Citation

Witsil, Joanne C; Mycyk, Mark B. (2017). Haloperidol, a Novel Treatment for Cannabinoid Hyperemesis Syndrome.. American journal of therapeutics, 24(1), e64-e67. https://doi.org/10.1097/MJT.0000000000000157